Genome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, China

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Qi, Lu Nan ^a   Li, Le Qun ^a   Chen, Yuan Yuan ^a   Chen, Zhao Hong ^a   Bai, Tao ^a   Xiang, Bang De ^a   Qin, Xiao ^a   Xiao, Kai Yin ^a   Peng, Min Hao ^a   Liu, Zhi Ming ^a   Liu, Tang Wei ^a   Qin, Xue ^a   Li, Shan ^a   Han, Ze Guang ^b   Mo, Zeng Nan ^a   Santella, Regina M ^c   Winkler, Cheryl A ^d   O'Brien, Stephen J ^d   Peng, Tao ^a,d  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^c Department of Medicine   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; ALDO KETO REDUCTASE FAMILY 1 MEMBER B10; MESSENGER RNA; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ADULT; AGED; AKR1B10 GENE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHINA; CHROMOSOME 4Q; CHROMOSOME 7Q; CHROMOSOME 8P; CHROMOSOME ABERRATION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; AFLATOXIN B1; AGED; ALDEHYDE REDUCTASE; CARCINOMA, HEPATOCELLULAR; CHINA; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE-FREE SURVIVAL; FEMALE; GENE DOSAGE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEOMICS; RISK; RNA, MESSENGER; RNA, NEOPLASM; YOUNG ADULT;

EID: 84896739321     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083465     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. Gao J, Xie L, Yang WS, Zhang W, Gao S et al. (2012) Risk factors of hepatocellular carcinoma - current status and perspectives. Asian Pac J Cancer Prev 13: 743-752. doi:10.7314/APJCP.2012.13.3.743. PubMed: 22631642.
3. Cabibbo G, Craxì A (2010) Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 14: 352-355. PubMed: 20496547.
4. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ et al. (1989) Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 49: 2506-2509. PubMed: 2539905. (Pubitemid 19125586)
5. Jackson PE, Groopman JD (1999) Aflatoxin and liver cancer. Baillieres Best Pract Res Clin Gastroenterol 13: 545-555. doi:10.1053/bega.1999.0047. PubMed: 10654919. (Pubitemid 30050458)
6. Aravalli RN, Steer CJ, Cressman EN (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48: 2047-2063. doi:10.1002/hep.22580. PubMed: 19003900.
7. Liu ZM, Li LQ, Peng MH, Liu TW, Qin Z et al. (2008) Hepatitis B virus infection contributes to oxidative stress in a population exposed to aflatoxin B1 and high-risk for hepatocellular carcinoma. Cancer Lett 263: 212-222. doi:10.1016/j.canlet.2008.01.006. PubMed: 18280645.
8. Wild CP, Turner PC (2002) The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 17: 471-481. doi:10.1093/mutage/17.6.471. PubMed: 12435844. (Pubitemid 35414775)
9. Bedard LL, Massey TE (2006) Aflatoxin B1-induced DNA damage and its repair. Cancer Lett 241: 174-183. doi:10.1016/j.canlet.2005.11.018. PubMed: 16458422. (Pubitemid 44163046)
10. Katiyar S, Dash BC, Thakur V, Guptan RC, Sarin SK et al. (2000) P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer 88: 1565-1573. doi:10.1002/(SICI)1097-0142(20000401)88:7. PubMed: 10738214. (Pubitemid 30183141)
11. Su Q, Schröder CH, Otto G, Bannasch P (2000) Overexpression of p53 protein is not directly related to hepatitis B x protein expression and is associated with neoplastic progression in hepatocellular carcinomas rather than hepatic preneoplasia. Mutat Res 462: 365-380. doi:10.1016/S1383-5742(00)00026-0. PubMed: 10767646. (Pubitemid 30190242)
12. Besaratinia A, Kim SI, Hainaut P, Pfeifer GP (2009) In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology 137: 1127-1137, e1121-1125
13. Gouas D, Shi H, Hainaut P (2009) The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett 286: 29-37. doi:10.1016/j.canlet.2009.02.057. PubMed: 19376640.
14. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC (2003) TP53 and liver carcinogenesis. Hum Mutat 21: 201-216. doi:10.1002/humu.10176. PubMed: 12619106. (Pubitemid 36292963)
15. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T et al. (2002) Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 62: 3939-3944. PubMed: 12124323. (Pubitemid 34791056)
16. Kim W, Oe Lim S, Kim JS, Ryu YH, Byeon JY et al. (2003) Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res 9: 5493-5500. PubMed: 14654528. (Pubitemid 37499467)
17. Hashimoto K, Mori N, Tamesa T, Okada T, Kawauchi S et al. (2004) Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol 17: 617-622. doi:10.1038/modpathol.3800107. PubMed: 15133472. (Pubitemid 38715482)
18. Patil MA, Gütgemann I, Zhang J, Ho C, Cheung ST et al. (2005) Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis 26: 2050-2057. doi:10.1093/carcin/bgi178. PubMed: 16000397. (Pubitemid 41672192)
19. Kim TM, Yim SH, Shin SH, Xu HD, Jung YC et al. (2008) Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer 123: 2808-2815. doi:10.1002/ijc.23901. PubMed: 18803288.
20. Taniguchi K, Yamada T, Sasaki Y, Kato K (2010) Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma. BMC Cancer 10: 530. doi:10.1186/1471-2407-10-530. PubMed: 20923573.
21. Xue KX (2005) Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis. Ai Zheng 24: 757-768. PubMed: 15946497.
22. Shirabe K, Toshima T, Taketomi A, Taguchi K, Yoshizumi T et al. (2011) Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan. Liver Int 31: 1366-1372. doi:10.1111/j.1478-3231.2011.02572.x. PubMed: 21745313.
23. Nishida N, Goel A (2011) Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics 12: 130-137. doi:10.2174/138920211795564359. PubMed: 21966251.
24. Varma G, Varma R, Huang H, Pryshchepava A, Groth J et al. (2005) Array comparative genomic hybridisation (aCGH) analysis of premenopausal breast cancers from a nuclear fallout area and matched cases from Western New York. Br J Cancer 93: 699-708. doi:10.1038/sj.bjc.6602784. PubMed: 16222315. (Pubitemid 41486462)
25. Qin LX, Tang ZY, Ye SL, Liu YK, Ma ZC et al. (2001) Chromosome 8p deletion is associated with metastasis of human hepatocellular carcinoma when high and low metastatic models are compared. J Cancer Res Clin Oncol 127: 482-488. doi:10.1007/s004320100236. PubMed: 11501747.
26. Wong N, Lai P, Pang E, Fung LF, Sheng Z et al. (2000) Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin Cancer Res 6: 4000-4009. PubMed: 11051249.
27. Blanquet V, Garreau F, Chenivesse X, Brechot C, Turleau C (1988) Regional mapping to 4q32.1 by in situ hybridization of a DNA domain rearranged in human liver cancer. Hum Genet 80: 274-276. doi:10.1007/BF01790096. PubMed: 2847975.
28. Buetow KH, Murray JC, Israel JL, London WT, Smith M et al. (1989) Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. Proc Natl Acad Sci U S A 86: 8852-8856. doi:10.1073/pnas.86.22.8852. PubMed: 2573067. (Pubitemid 20010323)
29. Pasquinelli C, Garreau F, Bougueleret L, Cariani E, Grzeschik KH et al. (1988) Rearrangement of a common cellular DNA domain on chromosome 4 in human primary liver tumors. J Virol 62: 629-632. PubMed: 2826820. (Pubitemid 18064210)
30. Moinzadeh P, Breuhahn K, Stützer H, Schirmacher P (2005) Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade - results of an explorative CGH meta-analysis. Br J Cancer 92: 935-941. doi:10.1038/sj.bjc.6602448. PubMed: 15756261. (Pubitemid 40462642)
31. Zhou T, Evans AA, London WT, Xia X, Zou H et al. (1997) Glutathione S-transferase expression in hepatitis B virus-associated human hepatocellular carcinogenesis. Cancer Res 57: 2749-2753. PubMed: 9205086. (Pubitemid 27283789)
32. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML et al. (1995) Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci U S A 92: 2384-2387. doi:10.1073/pnas.92.6.2384. PubMed: 7892276.
33. Jäättelä M (1999) Escaping cell death: survival proteins in cancer. Exp Cell Res 248: 30-43. doi:10.1006/excr.1999.4455. PubMed: 10094811.
34. Blagosklonny MV (2001) Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 93: 239-240. doi:10.1093/jnci/93.3.239. PubMed: 11158196.
35. Helmbrecht K, Zeise E, Rensing L (2000) Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 33: 341-365. doi:10.1046/j.1365-2184.2000.00189.x. PubMed: 11101008.
36. Lebret T, Watson RW, Molinié V, O'Neill A, Gabriel C et al. (2003) Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer 98: 970-977. doi:10.1002/cncr.11594. PubMed: 12942564. (Pubitemid 37022097)
37. Pomara G, Cappello F (2003) RE: Heat shock proteins: their role in urological tumors. J Urol 170: 927-928. doi:10.1097/01.ju.0000080564.23671.32. PubMed: 12913740. (Pubitemid 36999600)
38. Didelot C, Schmitt E, Brunet M, Maingret L, Parcellier A et al. (2006) Heat shock proteins: endogenous modulators of apoptotic cell death. Handb Exp Pharmacol: 171-198. PubMed: 16610360.
39. Paul C, Simon S, Gibert B, Virot S, Manero F et al. (2010) Dynamic processes that reflect anti-apoptotic strategies set up by HspB1 (Hsp27). Exp Cell Res 316: 1535-1552. doi:10.1016/j.yexcr.2010.03.006. PubMed: 20233592.
40. Gupta SD, Gomes A, Debnath A, Saha A, Gomes A (2010) Apoptosis induction in human leukemic cells by a novel protein Bengalin, isolated from Indian black scorpion venom: through mitochondrial pathway and inhibition of heat shock proteins. Chem Biol Interact 183: 293-303. doi:10.1016/j.cbi.2009.11.006. PubMed: 19913524.
41. van Noort JM, Bsibsi M, Nacken P, Gerritsen WH, Amor S (2012) The link between small heat shock proteins and the immune system. Int J Biochem Cell Biol 44: 1670-1679. doi:10.1016/j.biocel.2011.12.010. PubMed: 22233974.
42. Sun W, Xing B, Sun Y, Du X, Lu M et al. (2007) Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol Cell Proteomics 6: 1798-1808. doi:10.1074/mcp.M600449-MCP200. PubMed: 17627933. (Pubitemid 350031681)
43. Hu J, Seeger C (1996) Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci U S A 93: 1060-1064. doi:10.1073/pnas.93.3.1060. PubMed: 8577714. (Pubitemid 26052842)
44. Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A et al. (2005) Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 11: 1776-1785. doi:10.1158/1078-0432.CCR-04-1238. PubMed: 15755999. (Pubitemid 40471839)
45. Zhong L, Shen H, Huang C, Jing H, Cao D (2011) AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol Appl Pharmacol 255: 40-47. doi:10.1016/j.taap.2011.05.014. PubMed: 21640744.
46. Kang MW, Lee ES, Yoon SY, Jo J, Lee J et al. (2011) AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer. J Int Med Res 39: 78-85. doi:10.1177/147323001103900110. PubMed: 21672310.
47. Chung YT, Matkowskyj KA, Li H, Bai H, Zhang W et al. (2012) Overexpression and oncogenic function of aldo-keto reductase family 10 (AKR1B10) in pancreatic carcinoma. Mod Pathol 25: 758-766. doi:10.1038/modpathol.2011. 191. PubMed: 22222635.
48. Li CP, Goto A, Watanabe A, Murata K, Ota S et al. (2008) AKR1B10 in usual interstitial pneumonia: expression in squamous metaplasia in association with smoking and lung cancer. Pathol Res Pract 204: 295-304. doi:10.1016/j.prp.2006. 12.012. PubMed: 18358633.
49. Wang C, Yan R, Luo D, Watabe K, Liao DF et al. (2009) Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 284: 26742-26748. doi:10.1074/jbc.M109. 022897. PubMed: 19643728.